Research progress of mechanism about Jinghua Weikang capsule against Helicobacter pylori
-
摘要: 幽门螺杆菌(Helicobacter pylori，HP)是对人体健康造成严重威胁的一种细菌，全球感染率高，且耐药性高。荆花胃康胶丸在抗HP治疗方面取得了一定的临床效果，但其作用机制不详。荆花胃康胶丸主要通过影响NF-κB信号通路发挥抗HP作用；抑制HP生物膜的形成来提升抗生素的作用效率，同时还可降低抗生素的最低抑菌浓度，协同抗生素根除HP并逆转抗生素的耐药性；可改善HP感染后的肠道菌群结构，使有益菌群丰度增加，有害菌群数量减少；还能修复HP感染后损伤的胃黏膜，使胃黏膜上皮细胞形态恢复正常。本文对荆花胃康胶丸抗HP的作用机制进行综述。Abstract: Helicobacter pylori(HP) is a kind of bacteria that plays a serious threat to human health in the world, with a high global infection rate and high drug resistance.Jinghua Weikang capsule has got certain clinical effect in the treatment of HP, but its mechanism is still unknown. The results showed that Jinghua Weikang capsule anti-HP mainly by affecting NF-κB signaling pathway. It can inhibit the formation of HP biofilm then improve the efficiency of antibiotics, also can reduce the minimum inhibitory concentration of antibiotics, and cooperate with antibiotics to eradicate HP and reverse antibiotic resistance. It can also improve the intestinal flora structure after HP infected, increase the abundance of beneficial flora and decrease the number of harmful flora. It can also repair the damaged gastric mucosa after HP infected and restore the morphology of gastric mucosal epithelial cells to normal. In this paper, we will review the mechanism of Jinghua Weikang capsules against HP in detail.
-
-
[1] 中华医学会消化病学分会幽门螺杆菌学组. 2022中国幽门螺杆菌感染治疗指南[J]. 中华消化杂志, 2022, 8(11): 745-756. doi: 10.3760/cma.j.cn311367-20220929-00479
[2] Chiang TH, Chang WJ, Chen SL, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands[J]. Gut, 2021, 70(2): 243-250.
[3] Zhong ZS, Zhan BJ, Xu BH, et al. Emphasizing the importance of successful eradication of Helicobacter pylori on initial treatment[J]. Am J Cancer Res, 2022, 12(3): 1215-1221.
[4] Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance-from biology to clinical implications[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(9): 613-629. doi: 10.1038/s41575-021-00449-x
[5] Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis[J]. Lancet Infect Dis, 2018, 18(3): 318-327. doi: 10.1016/S1473-3099(17)30753-3
[6] 赵瑞顺. 荆花胃康胶丸抗幽门螺杆菌的药理及临床应用进展[J]. 天津药学, 2020, 32(4): 58-62. doi: 10.3969/j.issn.1006-5687.2020.04.021
[7] 李建勋, 吕宾, 杜勤, 等. 荆花胃康胶丸联合铋剂四联治疗幽门螺杆菌阳性慢性胃炎多中心随机对照研究[J]. 中国中西医结合消化杂志, 2018, 26(12): 998-1004. https://zxyxh.whuhzzs.com/article/doi/10.3969/j.issn.1671-038X.2018.12.06
[8] 杨琼, 尚琪, 魏国强, 等. 含铋剂四联方案联合荆花胃康胶丸治疗幽门螺杆菌感染的前瞻性多中心随机对照研究[J]. 中华医学杂志, 2019, 99(4): 295-300. doi: 10.3760/cma.j.issn.0376-2491.2019.04.012
[9] 李永宇, 韩红梅. 荆花胃康胶丸联合四联疗法在幽门螺杆菌感染的慢性胃炎患者中的应用效果[J]. 中国实用医药, 2020, 15(1): 133-135. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA202001063.htm
[10] 王楠楠, 潘婷婷. 荆花胃康胶丸联合含铋剂四联疗法对慢性胃炎合并Hp感染患者血清炎症因子和胃黏膜标志物的影响[J]. 中国卫生工程学, 2022, 8(3): 499-501, 504. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWX202203052.htm
[11] Napetschnig J, Wu H. Molecular basis of NF-κB signaling[J]. Annu Rev Biophys, 2013, 42: 443-468. doi: 10.1146/annurev-biophys-083012-130338
[12] Mitchell JP, Carmody RJ. NF-κB and the transcriptional control of inflammation[J]. Int Rev Cell Mol Biol, 2018, 335: 41-84.
[13] Zhu SM, Al-Mathkour M, Cao LL, et al. CDK1 bridges NF-κB and β-catenin signaling in response to H. pylori infection in gastric tumorigenesis[J]. Cell Rep, 2023, 42(1): 112005. doi: 10.1016/j.celrep.2023.112005
[14] Zhou P, She Y, Dong N, et al. Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose[J]. Nature, 2018, 561(7721): 122-126. doi: 10.1038/s41586-018-0433-3
[15] Sokolova O, Kähne T, Bryan K, et al. Interactome analysis of transforming growth factor-β-activated kinase 1 in Helicobacter pylori-infected cells revealed novel regulators tripartite motif 28 and CDC37[J]. Oncotarget, 2018, 9(18): 14366-14381. doi: 10.18632/oncotarget.24544
[16] Maubach G, Lim MCC, Sokolova O, et al. TIFA has dual functions in Helicobacter pylori-induced classical and alternative NF-κB pathways[J]. EMBO Rep, 2021, 22(9): e52878. doi: 10.15252/embr.202152878
[17] Maubach G, Vieth M, Boccellato F, et al. Helicobacter pylori-induced NF-κB: trailblazer for gastric pathophysiology[J]. Trends Mol Med, 2022, 28(3): 210-222. doi: 10.1016/j.molmed.2021.12.005
[18] 胡奕, 何晨, 吕农华. 核因子κB信号通路在幽门螺杆菌致病中的作用[J]. 中华消化杂志, 2020, 40(11): 790-792. doi: 10.3760/cma.j.cn311367-20190313-00114
[19] Doger FK, Meteoglu I, Ozkara E, et al. Expression of NF-kappaB in Helicobacter pylori infection[J]. Dig Dis Sci, 2006, 51(12): 2306-2309. doi: 10.1007/s10620-006-9352-5
[20] 叶晖, 于靖, 张学智. 土荆芥挥发油对小鼠体内幽门螺杆菌清除作用及对NF-κB表达的影响[J]. 中华中医药杂志, 2017, 32(12): 5346-5349. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201712025.htm
[21] Shi Z, Ye H, Yu J, et al. Jinghua Weikang capsule protects against Helicobacter pylori-induced inflammatory responses via the nuclear factor-kappa B signaling pathway[J]. J Tradit Chin Med, 2018, 38(3): 366-372. doi: 10.1016/j.jtcm.2018.03.001
[22] 洪盛威, 杨尧, 徐丁林, 等. 基于系统药理学方法探究荆花胃康胶丸干预幽门螺杆菌所致炎症反应机制[J]. 安徽科技学院学报, 2021, 35(2): 57-66. https://www.cnki.com.cn/Article/CJFDTOTAL-ANJS202102012.htm
[23] Flemming HC, van Hullebusch ED, Neu TR, et al. The biofilm matrix: multitasking in a shared space[J]. Nat Rev Microbiol, 2023, 21(2): 70-86. doi: 10.1038/s41579-022-00791-0
[24] Suci PA, Mittelman MW, Yu FP, et al. Investigation of ciprofloxacin penetration into Pseudomonas aeruginosa biofilms[J]. Antimicrob Agents Chemother, 1994, 38(9): 2125-2133. doi: 10.1128/AAC.38.9.2125
[25] Rather MA, Gupta K, Mandal M. Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies[J]. Publ Braz Soc Microbiol, 2021, 52(4): 1701-1718. doi: 10.1007/s42770-021-00624-x
[26] Hou C, Yin FX, Wang S, et al. Helicobacter pylori biofilm-related drug resistance and new developments in its anti-biofilm agents[J]. Infect Drug Resist, 2022, 15: 1561-1571. doi: 10.2147/IDR.S357473
[27] Doohan D, Rezkitha YAA, Waskito LA, et al. Helicobacter pylori BabA-SabA key roles in the adherence phase: the synergic mechanism for successful colonization and disease development[J]. Toxins, 2021, 13(7): 485. doi: 10.3390/toxins13070485
[28] Matos R, Amorim I, Magalhães A, et al. Adhesion of Helicobacter species to the human gastric mucosa: a deep look into glycans role[J]. Front Mol Biosci, 2021, 8: 656439. doi: 10.3389/fmolb.2021.656439
[29] Fu HW, Lai YC. The role of Helicobacter pylori Neutrophil-activating protein in the pathogenesis of H. pylori and beyond: from a virulence factor to therapeutic targets and therapeutic agents[J]. Int J Mol Sci, 2022, 24(1): 91. doi: 10.3390/ijms24010091
[30] Krzyżek P, Grande R, Migdał P, et al. Biofilm formation as a complex result of virulence and adaptive responses of Helicobacter pylori[J]. Pathogens, 2020, 9(12): E1062. doi: 10.3390/pathogens9121062
[31] Jia X, Huang Q, Lin M, et al. Revealing the novel effect of Jinghua Weikang capsule against the antibiotic resistance of Helicobacter pylori[J]. Front Microbiol, 2022, 13: 962354. doi: 10.3389/fmicb.2022.962354
[32] 张恩恩, 叶晖, 贾晓芬, 等. 土荆芥提取物在体外对幽门螺杆菌生物膜的作用[J]. 中国中西医结合杂志, 2020, 40(10): 1241-1245. doi: 10.7661/j.cjim.20200904.334
[33] Yang I, Woltemate S, Piazuelo MB, et al. Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia[J]. Sci Rep, 2016, 6: 18594. doi: 10.1038/srep18594
[34] Alarcón T, Llorca L, Perez-Perez G. Impact of the microbiota and gastric disease development by Helicobacter pylori[J]. Curr Top Microbiol Immunol, 2017, 400: 253-275.
[35] Wang Z, Shao SL, Xu XH, et al. Helicobacter pylori and gastric microbiota homeostasis: progress and prospects[J]. Future Microbiol, 2023, 18: 137-157. doi: 10.2217/fmb-2022-0102
[36] 史宗明, 于靖, 黄秋月, 等. 土荆芥对幽门螺杆菌感染小鼠肠道菌群多样性的影响[J]. 北京中医药, 2018, 37(10): 932-937. https://www.cnki.com.cn/Article/CJFDTOTAL-BJZO201810008.htm
[37] Veenendaal RA, Woudt SHS, Schoffelen AF, et al. Important rise in antibiotic resistance rates in Helicobacter pylori in the Netherlands[J]. Ned Tijdschr Geneeskd, 2022, 166: D6434.
[38] Ho JJC, Navarro M, Sawyer K, et al. Helicobacter pylori antibiotic resistance in the United States between 2011 and 2021: a systematic review and meta-analysis[J]. Am J Gastroenterol, 2022, 117(8): 1221-1230. doi: 10.14309/ajg.0000000000001828
[39] Xu WY, Yang BT, Lin L, et al. Antibiotic resistance of Helicobacter pylori in Chinese children: a multicenter study from 2016 to 2023[J]. Helicobacter, 2024, 29(1): e13038. doi: 10.1111/hel.13038
[40] Hathroubi S, Zerebinski J, Clarke A, et al. Helicobacter pylori biofilm confers antibiotic tolerance in part via A protein-dependent mechanism[J]. Antibiotics, 2020, 9(6): 355. doi: 10.3390/antibiotics9060355
[41] 于靖, 张学智, 史宗明, 等. 土荆芥挥发油对幽门螺杆菌甲硝唑耐药株及敏感株的体外抗菌作用研究[J]. 北京中医药, 2018, 37(10): 929-931. https://www.cnki.com.cn/Article/CJFDTOTAL-BJZO201810007.htm
[42] Ansari S, Yamaoka Y. Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity[J]. Toxins, 2019, 11(11): 677. doi: 10.3390/toxins11110677
[43] 张思依, 吕文亮, 徐婧, 等. 基于NLRP3炎症小体通路探讨连朴饮对幽门螺杆菌感染大鼠胃黏膜损伤的保护机制[J]. 时珍国医国药, 2023, 9(1): 81-84. https://www.cnki.com.cn/Article/CJFDTOTAL-SZGY202301020.htm
[44] 曹名波, 董蕾, 苌新明, 等. 土荆芥-水团花对胃溃疡大鼠黏膜保护作用的研究[J]. 中国中药杂志, 2007, 32(1): 49-52. doi: 10.3321/j.issn:1001-5302.2007.01.014
[45] 叶晖, 李宁, 张学智, 等. 荆花胃康胶丸对小鼠体内H. pylori的根除作用及对胃黏膜上皮细胞形态的影响[J]. 中国中西医结合消化杂志, 2014, 22(7): 351-354. doi: 10.3969/j.issn.1671-038X.2014.07.01
[46] 周汀, 刘斌, 李善高. 幽门螺杆菌感染治疗的研究进展[J]. 国际消化病杂志, 2021, 41(2): 96-99. doi: 10.3969/j.issn.1673-534X.2021.02.006
[47] 吕一鸣, 秦向荣, 于静, 等. 伏诺拉生在幽门螺杆菌根除治疗中作用及影响因素的研究进展[J]. 国际消化病杂志, 2023, 43(3): 141-145. doi: 10.3969/j.issn.1673-534X.2023.03.002
-
计量
- 文章访问数: 355
- 施引文献: 0
下载: